Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives
Open Access
Abstract
The management of CSPH in patients undergoing systemic treatment for HCC has emerged as a critical concern due to the absence of reliable diagnostic criteria and uncertainties surrounding therapeutic approaches. This review aims to underscore the primary pathophysiological aspects linking HCC and PH, while also addressing the current and emerging clinical strategies for the management of portal hypertension. A review of studies from January 2003 to June 2023 was conducted using the PubMed database and employing MeSH terms, such as “hepatocellular carcinoma”, “immune checkpoint inhibitors”, “systemic therapy”, “portal hypertension”, “variceal bleeding” and “tyrosine kinase inhibitors”. Despite promising results of tyrosine kinase inhibitors in animal models for PH and fibrosis, only Sorafenib has demonstrated similar effects in human studies, whereas Lenvatinib appears to promote PH development. The impact of Atezolizumab/Bevacizumab on PH remains uncertain, with an increasing risk of bleeding related to Bevacizumab in patients with prior variceal hemorrhage. Given the absence of specific guidelines, endoscopic surveillance during treatment is advisable, and primary and secondary prophylaxis of variceal bleeding should adhere to the Baveno VII recommendations. Furthermore, in patients with advanced HCC, refinement of diagnostic criteria for CSPH and guidelines for its surveillance are warranted.Keywords
This publication has 107 references indexed in Scilit:
- Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child‐Pugh B cirrhosisCancer Medicine, 2022
- Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world studyHepatology, 2022
- Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019Cancer Medicine, 2022
- FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with SorafenibThe Oncologist, 2021
- Nivolumab in patients with advanced hepatocellular carcinoma and Child‐Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case seriesCancer, 2019
- Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenibHepatology, 2015
- Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forcesHepatology, 2014
- Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats #Hepatology, 2009
- Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in ratsHepatology, 2007
- Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic ratsHepatology, 1998